Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).
Douglas R. Adkins(Washington University in St. Louis), Makoto Tahara(National Cancer Center Hospital East), Justin Hoffman(Pfizer (United States)), Bohuslav Melichar(Palacký University Olomouc), Jin‐Ching Lin(Changhua Christian Hospital), Assuntina G. Sacco(University of California San Diego), Shaw-Ling Wang(Pfizer (United States)), Kenneth A. Kern(Pfizer (United States)), Qi Shen(Qingdao University), Peter Oppelt(Washington University in St. Louis), Holger Thurm(Pfizer (United States)), Jean‐François Martini(Hôpital Necker-Enfants Malades), Jessica Ley(Washington University in St. Louis)
Cited by 18
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k